Last reviewed · How we verify
Autologous DC Therapy
Autologous dendritic cells are loaded with tumor antigens to stimulate a patient-specific immune response against cancer cells.
Autologous dendritic cells are loaded with tumor antigens to stimulate a patient-specific immune response against cancer cells. Used for Advanced solid tumors.
At a glance
| Generic name | Autologous DC Therapy |
|---|---|
| Sponsor | Diakonos Oncology Corporation |
| Drug class | cell therapy |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
This therapy involves the extraction of dendritic cells from the patient, which are then pulsed with tumor antigens and reinfused into the patient to enhance the immune system's ability to recognize and destroy cancer cells.
Approved indications
- Advanced solid tumors
Common side effects
- Fatigue
- Fever
- Chills
Key clinical trials
- Exploratory Clinical Study of Targeted Activated DC and CAR-T Therapy in Advanced Solid Cancers (EARLY_PHASE1)
- ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients (PHASE1)
- IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma (PHASE1)
- Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer (PHASE1, PHASE2)
- Exploratory Clinical Study of Claudin18.2-Targeted Activated DC and CAR-T Therapy in Advanced Pancreatic Cancer. (EARLY_PHASE1)
- Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas (PHASE1)
- Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML (PHASE1)
- Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Autologous DC Therapy CI brief — competitive landscape report
- Autologous DC Therapy updates RSS · CI watch RSS
- Diakonos Oncology Corporation portfolio CI